- Home
- Healthcare professionals
- ACE Technology Guidances
- Drug Guidance
Drug Guidance
View all drug guidances and its details here.
170 articles
1 August 2025
Update of MOH List of Subsidised Drugs to include treatments for various cancer conditions
Condition
Cancer
Drug guidance
1 August 2025
Review of cancer drugs for previously treated advanced hepatocellular carcinoma
Condition
Cancer
Liver
Drug guidance
1 August 2025
Review of cancer drugs for treating advanced urothelial carcinoma
Condition
Cancer
Urological
Drug guidance
1 August 2025
Pembrolizumab for treating persistent, recurrent, or metastatic cervical cancer
Condition
Cancer
Gynaecological
Drug guidance
1 August 2025
Immune checkpoint inhibitors and BRAF/MEK inhibitors for treating advanced malignant melanoma
Condition
Cancer
Skin
Drug guidance
1 August 2025
Bevacizumab biosimilar for treating different types of cancers
Condition
Cancer
Drug guidance
1 August 2025
Review of cancer drugs for previously treated multiple myeloma
Condition
Cancer
Blood and Immune System
Drug guidance
1 August 2025
Tislelizumab for treating non-small-cell lung cancer, oesophageal squamous cell carcinoma, and nasopharyngeal carcinoma
-
Feature Articles
1 August 2025
Tislelizumab for treating locally advanced or metastatic non-squamous non-small-cell lung cancer without EGFR or ALK genomic tumour aberrations
-
Feature Articles
4 June 2025
Alectinib for adjuvant treatment of resectable, ALK mutation-positive non-small-cell lung cancer
Condition
Cancer
Respiratory
-
Drug guidance